Why Atossa Therapeutics Blasted 30% Higher on Monday

Atossa Therapeutics (NASDAQ: ATOS) got off to a roaring start this week, with its stock closing just over 30% higher on Monday to reach a new one-year peak. The company announced that clinical results for a promising pipeline drug are coming in a matter of days.

Atossa, a clinical-stage biotech that has been popular with investors of late, said it would publish and discuss final data from the phase 2 study of Endoxifen. This is the company's leading pipeline treatment, a drug that is given to breast cancer patients in advance of surgery. The discussion will take place in a webinar this Wednesday at 8 a.m. PDT; it is to be led by company CEO Steven Quay and other top managers.

Image source: Getty Images.

Continue reading

Source Fool.com